aibio
Distress ·
Zeo ScientifiX says it cannot file its eight-month transition report on time
The Form 10-KT covers the eight months ended June 30, 2026. The company expects to file within the 15-day grace period.
ZEOX Zeo ScientifiX Inc.
Zeo ScientifiX (ZEOX) news
Latest Zeo ScientifiX news
- Financings
Zeo ScientifiX issues 100,000 shares and warrants for 500,000 shares to a consultant
The company also granted fully vested options at $2.86 per share to its interim chief executive and directors.
What Zeo ScientifiX does
Zeo ScientifiX Inc. is a clinical-stage biopharmaceutical company focused on biological therapeutics for degenerative diseases and regenerative medicine. Its products are derived from birth tissue, including mesenchymal stem cells, stem cell and amniotic fluid derived exosomes and Whartons Jelly matrix. Its principal product, Zofin, is derived from amniotic fluid and manufactured to retain naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles. The company also makes Patient Pure X (PPX), an autologous biologic containing a nanoparticle fraction precipitated from a patient's own peripheral blood. It sells its products through doctors and clinics and is positioning itself around Florida's stem cell therapy law, SB 1768, effective July 1, 2025. The company has obtained IND and emergency IND approvals from the FDA for clinical use of Zofin, and it has launched an IRB-approved study of PPX in patients with musculoskeletal joint pathologies. In June 2025 it acquired BioLumina, LLC, a seller of topical aesthetic products. It has also sued BioXtek, LLC in Broward County Circuit Court after BioXtek sought to terminate a joint venture.
| Product or program | What it is | Stage |
|---|---|---|
| Zofin | Amniotic fluid derived product retaining extracellular vesicles, proteins and nanoparticles | IND and emergency IND approvals obtained |
| Patient Pure X (PPX) | Autologous biologic with a nanoparticle fraction from the patient's own blood | IRB-approved clinical study launched |
| Topical aesthetic products | Topical aesthetic products using proprietary ingredients | begun to distribute |
Zeo ScientifiX annual financials
| Line | FY ended Oct 31, 2025 | FY ended Oct 31, 2024 |
|---|---|---|
| Revenue | $5.2 million | $4.6 million |
| Research and development | $100,000 | $164,000 |
| Net income (loss) | -$5.5 million | -$4.7 million |
| Cash from operations | -$718,000 | -$1.4 million |
| Cash and equivalents | $221,000 | $657,000 |
Questions about Zeo ScientifiX
What is the ticker symbol of Zeo ScientifiX?
Zeo ScientifiX Inc. trades under the ticker ZEOX on OTC.
Where is Zeo ScientifiX listed?
Zeo ScientifiX Inc. is listed on OTC.
What is the SEC CIK of Zeo ScientifiX?
The SEC Central Index Key (CIK) for Zeo ScientifiX Inc. is 1557376. Its filings are on SEC EDGAR.
How many shares does Zeo ScientifiX have outstanding?
7,837,441 shares as of 2026-06-12, per the cover page of its 10-Q filed 2026-06-15.
Which country or territory is Zeo ScientifiX listed under?
Our directory records Zeo ScientifiX Inc. under United States.
What does Zeo ScientifiX do?
Our directory classifies Zeo ScientifiX Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Zeo ScientifiX?
The ISIN recorded for Zeo ScientifiX Inc. is US68621D2062.
Does aibio.space cover Zeo ScientifiX?
aibio.space lists Zeo ScientifiX Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Zeo ScientifiX incorporated?
SEC records list its state or country of incorporation as NV.
What does Zeo ScientifiX develop?
Zeo ScientifiX Inc. is a clinical-stage biopharmaceutical company focused on biological therapeutics for degenerative diseases and regenerative medicine. Its products are derived from birth tissue, including mesenchymal stem cells, stem cell and amniotic fluid derived exosomes and Whartons Jelly matrix.
What is Zofin from Zeo ScientifiX?
Zofin: Amniotic fluid derived product retaining extracellular vesicles, proteins and nanoparticles Stage: IND and emergency IND approvals obtained.
What is Patient Pure X (PPX) from Zeo ScientifiX?
Patient Pure X (PPX): Autologous biologic with a nanoparticle fraction from the patient's own blood Stage: IRB-approved clinical study launched.
What was Zeo ScientifiX's revenue last year?
$5.2 million for the fiscal year ended Oct 31, 2025, as reported to the SEC.
Is Zeo ScientifiX profitable?
Zeo ScientifiX Inc. reported a net loss of $5.5 million for the fiscal year ended Oct 31, 2025, and used $718,000 of cash in operations, per its annual report to the SEC.
How much does Zeo ScientifiX spend on research and development?
$100,000 in the fiscal year ended Oct 31, 2025, per its annual report.
Investor discussion: Zeo ScientifiX
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,5.02). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Stock chart
SEC filings and registration
- SEC name
- Zeo ScientifiX, Inc.
- CIK
- 1557376
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- ZEOX (OTC)
- State or country of incorporation
- NV
- Fiscal year ends
- June 30
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 3321 COLLEGE AVENUE, DAVIE, FL, 33314
- Phone
- 888-963-7881
- Shares outstanding
- 7,837,441 as of 2026-06-12 (10-Q filed 2026-06-15)
- Former names
- Organicell Regenerative Medicine, Inc.; Biotech Products Services & Research, Inc.; BESPOKE TRICYCLES INC
Recent filings
Listing details
- Company
- Zeo ScientifiX Inc.
- Ticker
- ZEOX
- Listing
- OTC
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US68621D2062
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction